Avadel Pharmaceuticals (AVDL) Stock Analysis

What Avadel Pharmaceuticals does

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.

Key metrics

ETFs linked to AVDL

Broad-market and Healthcare sector ETFs an investor holding Avadel Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AVDL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Avadel Pharmaceuticals?

Avadel Pharmaceuticals trades under the ticker AVDL on NASDAQ.

Which exchange is AVDL listed on?

AVDL is listed on NASDAQ.

What sector does Avadel Pharmaceuticals operate in?

Avadel Pharmaceuticals is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze AVDL in a portfolio?

PortView shows AVDL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.